513 related articles for article (PubMed ID: 18058596)
21. Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.
Owens DR; Traylor L; Dain MP; Landgraf W
Diabetes Res Clin Pract; 2014 Nov; 106(2):264-74. PubMed ID: 25195151
[TBL] [Abstract][Full Text] [Related]
22. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
23. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
Fritsche A; Schweitzer MA; Häring HU;
Ann Intern Med; 2003 Jun; 138(12):952-9. PubMed ID: 12809451
[TBL] [Abstract][Full Text] [Related]
24. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
Kann PH; Wascher T; Zackova V; Moeller J; Medding J; Szocs A; Mokan M; Mrevlje F; Regulski M
Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):527-32. PubMed ID: 17115351
[TBL] [Abstract][Full Text] [Related]
25. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
[TBL] [Abstract][Full Text] [Related]
26. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice.
Hammer H; Klinge A
Int J Clin Pract; 2007 Dec; 61(12):2009-18. PubMed ID: 17997807
[TBL] [Abstract][Full Text] [Related]
27. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
28. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
29. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
Banerji MA; Baron MA; Gao L; Blonde L
Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
[TBL] [Abstract][Full Text] [Related]
30. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
31. Randomized, 1-year comparison of three ways to initiate and advance insulin for type 2 diabetes: twice-daily premixed insulin versus basal insulin with either basal-plus one prandial insulin or basal-bolus up to three prandial injections.
Riddle MC; Rosenstock J; Vlajnic A; Gao L
Diabetes Obes Metab; 2014 May; 16(5):396-402. PubMed ID: 24118931
[TBL] [Abstract][Full Text] [Related]
32. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
[TBL] [Abstract][Full Text] [Related]
33. Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial.
Jia W; Xiao X; Ji Q; Ahn KJ; Chuang LM; Bao Y; Pang C; Chen L; Gao F; Tu Y; Li P; Yang J
Lancet Diabetes Endocrinol; 2015 Apr; 3(4):254-62. PubMed ID: 25754414
[TBL] [Abstract][Full Text] [Related]
34. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness and Safety of Physician-Led Versus Patient-Led Titration of Insulin Glargine in Indian Patients with Type 2 Diabetes Mellitus: A Subanalysis of the Asian Treat to Target Lantus Study (ATLAS).
Misra A; Patel M; Agarwal P; Lodha S; Tandon N; Magdum M; Yajnik C; Ghosh R; Walekar A
Diabetes Technol Ther; 2019 Nov; 21(11):656-664. PubMed ID: 31335198
[No Abstract] [Full Text] [Related]
36. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis.
Sharplin P; Gordon J; Peters JR; Tetlow AP; Longman AJ; McEwan P
Cardiovasc Diabetol; 2009 Feb; 8():9. PubMed ID: 19220880
[TBL] [Abstract][Full Text] [Related]
37. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE.
Dornhorst A; Lüddeke HJ; Koenen C; Meriläinen M; King A; Robinson A; Sreenan S;
Diabetes Obes Metab; 2008 Jan; 10(1):75-81. PubMed ID: 18034846
[TBL] [Abstract][Full Text] [Related]
38. Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
Matyjaszek-Matuszek B; Lenart-Lipińska M; Rogalska D; Nowakowski A;
Endokrynol Pol; 2013; 64(5):375-82. PubMed ID: 24186595
[TBL] [Abstract][Full Text] [Related]
39. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
[TBL] [Abstract][Full Text] [Related]
40. The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.
Moon JS; Ha KS; Yoon JS; Lee HW; Lee HC; Won KC;
Acta Diabetol; 2014 Apr; 51(2):277-85. PubMed ID: 24445656
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]